This was a multinational, multicentre, double-blind Phase II study in Europe to evaluate the efficacy and safety of two dose regimens (200 mg bid and 200 mg tid) of sarpogrelate (MCI-9042, 5-HT 2A receptor antagonist) compared to placebo in patients with stable, moderately severe intermittent claudication. Following a singleblind placebo run-in period of 6 weeks, 364 (309 male and 55 female) patients (59.2 Ϯ 8.4 years, mean Ϯ SD) were randomized to receive sarpogrelate 200 mg bid, 200 mg tid or placebo for 24 weeks with a follow-up of 8 weeks. The primary objective was the increase of absolute claudication distance (ACD) at the end of treatment (week 24) compared to placebo. Analysis of covariance (ANCOVA) was performed on the log-transformed percentage of baseline ACD: log e (ACD/baseline). A responder analysis (defined as a Ն50% improvement in ACD) was also performed. There was a marked training/placebo effect on the ACD which persisted up to 16 weeks. At 24 weeks the primary objective did not reach statistical significance (200 mg bid vs placebo, p ϭ 0.225; 200 mg tid vs placebo, p ϭ 0.580). In the responder analysis, 200 mg bid showed a statistically significant difference vs placebo (p ϭ 0.035). In the exploratory analysis with completers (patients completing all treadmill tests), there was a statistical difference in ACD/baseline change for 200 mg bid (p ϭ 0.035) and in the responder analysis for 200 mg tid (p ϭ 0.044) at 24 weeks compared to placebo. Both treatments showed a carry-over effect for ACD during the 8-week follow-up (weeks 28-32). The treatment was well tolerated and no clinically significant safety concerns were reported. In conclusion, the study results confirm that sarpogrelate is well tolerated and although the primary endpoint failed to reach statistical significance, the responder analysis showed an increased absolute walking distance, which makes a further trial warranted, including a larger population, and possibly also a longer treatment period.
Introduction
Intermittent claudication is an important predictor for a generalized vascular disorder that reduces 5-year survival from about 90% to 70% compared to agematched controls. The risk of limb loss is only about 1% per year, 1 but symptoms in the leg may be disabling and require treatment. Revascularization is infrequently used but there is a reported increase in endovascular procedures. 2 Supervised exercise may improve walking capacity by 150%. 3 Pharmacotherapy, in the form of aspirin or clopidogrel, is generally given for the prevention of cardiovascular or cerebrovascular events, 4 while drugs to improve walking distance are used less frequently and with great variation between countries.
Based on the assumption that endogenous serotonin plays a role in the pathophysiology of intermittent claudication, selective 5-HT receptor antagonists such as ketanserin and naftidrofuryl have been investigated. Sarpogrelate (MCI-9042), a serotonin receptor antagonist with high specificity for 5-HT 2A receptors, 5, 6 is approved in Japan for the treatment of ischaemic symptoms resulting from chronic arterial occlusion. Sarpogrelate exerts its effects mainly through antiplatelet activity, 7 inhibition of vasoconstriction 8 and an increase of red cell deformability. 9 A previous Phase II study in the UK on the efficacy and safety of sarpogrelate 100 mg tid for 12 weeks followed by 200 mg tid for another 12 weeks vs placebo (Misubishi Pharma; data on file) encouraged the present study, the aim of which was to evaluate efficacy and safety and preliminary quality of life (QOL) data in patients with stable, moderately severe intermittent claudication, treated with sarpogrelate 200 mg bid and 200 mg tid. This study was designed according to the recommendations of the TransAtlantic Inter-Society Consensus (TASC) guidelines for clinical trials in intermittent claudication 1 and the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance. 10 
Methods

Study design
This was a multinational, multicentre, double-blind, placebo-controlled, randomized (1:1:1) three-arm study, with randomization stratified for diabetes. A single-blind, placebo, 6-week run-in period permitted stabilization of concomitant medications and baseline treadmill testing. Aspirin (75-160 mg daily, according to local practice) was to be taken as a supplemental concomitant medication throughout the study. Randomization to one of two doses of sarpogrelate (200 mg bid or 200 mg tid) or placebo occurred after successful completion of the run-in period.
Study medication was administered three times daily with two 100 mg tablets of sarpogrelate or matching placebo given in the morning, at noon or in the evening. During the run-in period, clinical assessments were performed at weeks Ϫ6, Ϫ3 and Ϫ1. Treatment with study medication continued for 24 weeks with seven visits at intervals of 4 weeks and follow-up assessments were performed at weeks 28 and 32. Safety assessments (vital signs, ECG, routine haematology and clinical chemistry) and treadmill tests were made at all visits. Ankle-brachial pressure index (ABPI) measurement, QOL evaluation, and assessment of lifestyle changes were made at baseline and at weeks 12, 24 and 32.
The administrative structure of this study included an international co-ordinating principal investigator, national co-ordinators, a Data Safety Monitoring Board (DSMB) and a Clinical Endpoint Committee (CEC). The study was conducted according to Good Clinical Practice, and Ethics Committee approval was obtained for each participating centre. Written informed consent was obtained from each patient before undergoing any of the screening procedures.
Patient population
Male or female patients aged 40-80 years were recruited into the study if they had suffered from chronic lower-extremity arterial occlusive disease (confirmed by duplex imaging) with symptoms of intermittent claudication (Fontaine stage II; Rutherford category 2) for at least 6 months, that in the opinion of the investigator had been stable during the past 3 months. In addition, an ABPI of 0.5-0.8, an absolute claudication distance (ACD) during run-in and at baseline between 100 and 400 m and previous instruction on lifestyle management were required.
Patients were excluded from participation if their initial claudication distance (ICD) was less than 50 m, and if exercise was limited due to symptoms other than intermittent claudication caused by atherosclerotic disease. Other major exclusion criteria were chronic critical limb ischemia, revascularization or sympathectomy or myocardial infarction within the preceding 6 months. With the exception of statins and aspirin, other antiplatelet drugs, anticoagulants, and drugs expected to exert effects on peripheral arteries or on the symptoms of claudication were not allowed.
Specific methods
A constant treadmill exercise test at 3.2 km/h and a 12% constant incline was performed for inclusion. The ACD measurement at week 4 had to be within Ϯ25% of the mean of the run-in and baseline values, otherwise the patient could not be randomized into the study. All centres underwent a quality control of the treadmill method before entering patients into the screening phase.
Statistics
All statistical tests were two-sided and at the 5% level of significance. Efficacy data were analysed for all randomized patients who received at least one dose of study medication, not including the placebo run-in period, and provided that at least one post-baseline assessment of ACD had been executed, following the principle of intention to treat. The primary efficacy variable was ACD at week 24. Analysis was performed on the log-transformed percentage of baseline ACD: log e (ACD/baseline). For the primary efficacy assessment the last observation carried forward (LOCF) was used to impute missing values only; all recorded ACD walking distances were used in the analysis regardless of the reason for stopping walking. The following variables were included in an analysis of covariance: presence of diabetes, centre (pooled), log e (baseline) and treatment. For the log-transformed percentage of baseline ACD at week 24, the estimates and associated 95% confidence intervals (CI) for the difference between each active treatment group and placebo was back-transformed to be presented as ratios. The logtransformed percentage of baseline ACD at week 24 was analysed using analysis of covariance (ANCOVA). A responder analysis was also performed on the ACD data at week 24 using logistic regression, including centre and presence of diabetes as covariates. A responder was defined as a patient whose walking distance at week 24 had improved by 50% or more from baseline. ICD was analysed using the same method as the primary efficacy variable. The above analyses were repeated for log e (ICD/baseline) and for the change from baseline of ABPI and QOL parameters (Medical Outcome Study Short Form 36 (SF 36) summary scores and Walking Impairment Questionnaire (PAD-WIQ) scores).
Safety data were summarized based on the safety population (all randomized patients who received at least one dose of study medication, not including the placebo run-in period). Morbidity was considered as a combined endpoint of all cases with any one of the predefined events that occurred after the first ingestion of study drug up to weeks 24 and 32. All-cause mortality and primary cause of death were recorded from randomization up to weeks 24 and 32.
It was assumed that randomization of 371 patients allowed for a drop-out rate of 15%. An expected difference in treatment effect of 22.5% required 315 evaluable patients (90% power, p Ͻ 0.05 significance level).
Results
Patient disposition and demographic data
A total of 452 patients were screened at 21 centres in four European countries (Germany, Hungary, Poland, Sweden) for participation in the study, of whom 88 patients did not meet the inclusion criteria. Thus, 364 (309 male, 55 female) patients (59.2 Ϯ 8.4 years, mean Ϯ SD, range 41-78 years), including 44 (12%) diabetics, were randomized into three groups: sarpogrelate 200 mg bid, 200 mg tid or placebo. Figure 1 shows the patient disposition and randomization among the three groups. The safety analysis was performed for all 364 patients. The efficacy analysis population included only 329 patients, due to issues related to the reporting of data from one centre.
For the exploratory analysis, patients who completed all treadmill testing from screening to week 32 were defined as the completer population.
One patient with low ACD (89 m) and one with low ICD (49 m) were included (protocol violations).
There were no statistically significant differences in the baseline characteristics of the three groups (Table 1) . Ten per cent (37 patients, Table 2 ) withdrew from the study at different time points, with no difference among the groups. There was, however, an uneven distribution of included patients among the countries as Poland included 181, Hungary 156, Germany 14 and Sweden 13 patients.
Efficacy
Absolute claudication distance (ACD) Figure 2 and Table 3 show the overall change (geometric mean) in ACD from baseline over the entire study in the efficacy analysis population. There was a marked training/placebo effect on the ACD which persisted up to 16 weeks, followed by separation of the two sarpogrelate groups from placebo. Regarding the primary efficacy endpoint, the geometric means for ACD/baseline change at week 24 for 200 mg bid (42%, p ϭ 0.225) and 200 mg tid (32%, p ϭ 0.580) were not statistically significant versus placebo (31%). During follow-up at week 28, the increase of ACD in the 200 mg bid group reached statistical significance ( p ϭ 0.039).
The proportion of responders who showed a Ͼ50% improvement in ACD was significantly higher for the 200 mg bid group than for placebo at week 24 ( p ϭ 0.035), and the difference also approached statistical significance at week 28 ( p ϭ 0.059) ( Table 4 ). The pattern of responses was similar for the completers population for both sarpogrelate groups. The differences in favour of sarpogrelate were statistically significant regarding the changes in the geometric mean of ACD from baseline for 200 mg bid at week 24, and also during follow-up (weeks 28 and 32) ( p ϭ 0.035, p ϭ 0.015 and p ϭ 0.043, respectively) ( Table 3 ). In the responder analysis, the 200 mg tid group reached a significant difference compared to placebo at week 24 ( p ϭ 0.044).
Initial claudication distance (ICD)
The ICD results (Figure 2 , Tables 3 and 4 ) showed a similar pattern to that for ACD. The geometric mean changes in ICD from baseline to week 24 for 200 mg bid, 200 mg tid and placebo were 44%, 42% and 37%, respectively. In the responder analysis, the percentage of patients who showed a 50% improvement in ICD from baseline at week 24 for 200 mg bid, 200 mg tid and placebo were 44%, 38% and 35%, respectively. These differences were not statistically significant. However, in the responder analysis with completers population, 200 mg bid showed a statistically significant difference (p ϭ 0.041) at week 24 and also at week 28 (p ϭ 0.001). Mean ABPI did not change from baseline to week 24 for any of the groups (0.64-0.67; 0.63-0.64; 0.63-0.64 for 200 mg bid, 200 mg tid and placebo, respectively). Neither the SF 36 nor the PAD-WIQ Tables 3 and 4 for ANCOVA results.) parameters changed significantly from baseline to week 24. Diabetic patients, constituting 11.6-12.4% in the three groups, did not differ from non-diabetic patients in any of the investigated parameters.
Safety
Total mortality was 0.8% (three patients): two patients in the placebo group (aortic emboli and malignant cardiac rhythm) and one in the 200 mg bid group (myocardial infarction). Morbidity endpoints occurred in five patients two (1.7%) in the placebo group (stroke and acute limb ischaemia), and three (2.5%) in the 200 mg bid group (angina, myocardial infarction and acute limb ischaemia) ( Table 5 ).
The overall incidences of treatment-related adverse events for 200 mg bid, 200 mg tid and placebo were 11.5%, 12.4% and 5.8%, respectively. Table 6 shows treatment-related adverse events reported with an incidence of more than 1%. The most frequent adverse events for patients treated with sarpogrelate were upper gastrointestinal complaints, an increase in liver enzymes and lower gastrointestinal complaints. There were no clinically significant changes in ECG including QTc, blood pressure and heart rate during the study. There were no deaths among those 10.4% of patients treated with concomitant potassium losing diuretics. Sarpogrelate treatment was well-tolerated and there were no clinically significant safety concerns.
Discussion
Besides lifestyle modification and exercise training, it is reasonable to search for drugs that appropriately reduce disabling claudication symptoms. The first drug that obtained approval was pentoxifyllin, nowadays rarely used due to recent study results about doubts on its efficacy. 11 Cilostazol, a phosphodiesterase type III inhibitor, has recently been evaluated in trials that have documented an increased walking ability and improved quality of life. 12, 13 This class of drugs is, however, contraindicated in patients with heart failure. Serotonin (5-HT) is a major non-peptidergic substance released from activated platelets, which mediates vasoconstriction and is involved in vascular inflammation leading to atherosclerosis. 14 
Serotonin
antagonists have been investigated for the treatment of intermittent claudication but the drugs in this class vary in their efficacy. Ketanserin has been found not to reduce claudication symptoms 15 and, furthermore, in combination with potassium-losing diuretics, to increase the number of deaths. 16 Reports suggest naftidrofuryl may improve quality of life 17 and walking distance in intermittent claudication, but with variable results. [18] [19] [20] [21] A recent study 22 of a novel selective 5-HT 2A receptor antagonist (AT-1015) did not show any evidence of efficacy in the treatment of intermittent claudication. In the present study on sarpogrelate (MCI-9042), which exhibits a selective antagonistic effect on 5-HT 2A receptors, and has a chemical structure different from ketanserin and AT-1015, 5, 6 there was a marked training/placebo effect on ACD which persisted up to 16 weeks, despite the 6-week placebo run-in period. The extent and variability in the placebo response has always been a major difficulty in evaluating drugs in intermittent claudication. Placebo-induced improvements in walking distance of more than 40% over baseline have been observed in several trials. [23] [24] [25] In another study a steady progressive improvement in claudication distance was reported for placebo increasing by 28% over 12 months. 15 This remarkable placebo effect is generally attributed to an improved exercise capacity from repeated examinations -a training effect. Furthermore, it is supposed that walking distance is strongly influenced by the subject's enhanced motivation in response to intense investigation.
It may be noted that there was great variation between patients at different centres regarding the use of treadmill tests. Some centres use treadmill tests routinely for diagnosis and follow-up, while patients at other centres had never experienced treadmill exercise before entering the screening phase of the present study.
From week 16 onwards the ACD change in the two sarpogrelate groups was separated from the placebo group, the latter levelling out. A similar pattern to ACD was seen for ICD. The effect was more pronounced in the sarpogrelate 200 mg bid group. However, in the completers population statistically significant differences were also observed for sarpogrelate 200 mg tid vs placebo.
The results suggest that sarpogrelate treatment may exert an effect on the claudication distance. The more pronounced effect in the 200 mg bid group may have arisen by chance as there were no differences in the distribution of patient characteristics at baseline. Pharmacokinetic simulations for sarpogrelate have shown that the C max of both the 200 mg bid and 200 mg tid regimens are the same (Mitsubishi Pharma; data on file). If the clinical effect on the claudication distance is a result of the C max of sarpogrelate (ie the 5-HT receptor is occupied at C max ), the effect of 200 mg bid and 200 mg tid would not differ.
An interesting observation of this study is that the effect of sarpogrelate on the ACD or ICD continued for 4-8 weeks after treatment had been discontinued. In other studies, 6 weeks after stopping cilostazol, patients lost 49% of the improvement of walking distance gained during the 24-week double-blind phase 26 and 48 weeks after discontinuation of naftidrofuryl, the improvement of ACD during 24 weeks of treatment decreased by more than 40%. 20 The observation that the effects of sarpogrelate carry over after treatment has been discontinued is interesting and should be investigated more in detail in the future. Although the mechanisms may be different it has been reported that sarpogrelate reduced restenosis after coronary stenting 27 and increased circulating adiponectin levels in diabetic patients with obliterative atherosclerosis, 28 findings that may support a more long-lasting effect of sarpogrelate.
From a safety perspective, the low mortality rate and low numbers of treatment-related adverse events, without clinically significant ECG changes is noteworthy, as they prove this drug differs from some former 5-HT-receptor antagonists. 16, 22 This study included an uneven distribution of patients, with only 7.5% of participants from Germany and Sweden. There is no reason to believe that the included population differed with regard to parameters important for the conclusions of this study. It was, however, learnt that the rather narrow window of ICD and ACD for inclusion prevented patients screened in Germany and Sweden from participation.
In conclusion, the study results confirm that sarpogrelate has a good safety profile and is well tolerated. It may exert an effect on the claudication distance, compared to placebo, although this was only proven in subgroup analyses of responders. A further trial is warranted, including a larger population, and possibly also a longer treatment and follow-up period to analyse a potential long-lasting effect of this treatment.
